Navigation Links
Grifols Signs Cooperative Agreement for Commercialization of Immunohematology Diagnostic Products in the US
Date:2/22/2011

BARCELONA, Spain, Feb. 22, 2011 /PRNewswire/ -- Grifols, a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain has entered into a long-term cooperative agreement with the diagnostics business of Novartis for the commercialization of select Grifols' diagnostic products in the US.  Under the terms of the agreement, Novartis will market and distribute Grifols' immunohematology instruments, assays and other products following US regulatory approvals.  The agreement also covers semi-automated pre-transfusion diagnostic products made by Grifols subsidiaries as well as Progenika blood group antigen genotyping products currently distributed by Grifols.

"Grifols' seventy year history of advancing blood diagnostics complements the Novartis leadership in blood safety and ongoing mission to advance preventive screening," said Oriol Dunach, the head of Diagnostic Grifols.  "Our commercialization agreement with Novartis will serve to enhance transfusion safety throughout the US by providing laboratories with the latest technologies and highest quality services," continued Dunach.  

Novartis is a trusted name in transfusion medicine that will help strengthen Grifols' position in the US blood transfusion market.  Novartis Diagnostics' highly sensitive tests and fully automated nucleic acid testing platforms, developed in partnership with Gen-Probe, are used to test millions of blood donations around the world each year for HIV, Hepatitis, and West Nile Virus.  Today, more than eighty percent of the US blood supply is tested on Novartis systems.  The commercialization agreement with Grifols will add immunohematology instruments to the portfolio of products Novartis Diagnostics can make available to blood banks and hospital transfusion centers.

This agreement leverages an earlier Grifols' distribution agreement with Spanish biotechnology company Progenika Biopharma for its microchip blood typing technology BLOODCHIP®.  Although the use of molecular biology tests in transfusion compatibility testing is still at its early stages, its use is expected to become more widespread as a result of hemovigilance and transfusion safety plans being introduced in many countries.

The agreement comes on the heels of the completion of a new Medion Grifols production facility in Switzerland that makes reagents for the rapid identification of blood groups.  It also follows a threefold production capacity increase for Grifols' immunohematology gel cards in 2009 at its Barcelona facility.  All of Grifols' diagnostic production facilities in Spain are ISO 13485 certified and meet leading industry standards for quality.  

About Grifols

Grifols is a Spanish holding company, specializing in the hospital-pharmaceutical sector, and with a presence in over 90 countries. Since May 2006 it has been listed on the Spanish Continuous Market, and since 2008 it has been included in the Ibex-35. It focuses on the research, development, manufacture and marketing of plasma products, diagnostic systems, intravenous therapies, enteral nutrition and medical supplies. In recent years Grifols has made significant investments in the area of transfusion medicine to ensure the strategic and technological position of the company in this area.


'/>"/>
SOURCE Grifols, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Health Robotics CytoCare(TM) Global Expansion Continues With Grifols International in Latin America
2. AMDL Diagnostics, Inc. Enters Into Exclusive Distribution Agreement With Grifols USA, LLC to Advance Commercialization of DR-70 Onko-Sure(TM) Cancer Test
3. Grifols Agrees to Acquire Intellectual Property for Treatment of Post-Polio Syndrome From Pharmalink AB
4. Health Robotics CytoCare Continues European Expansion With Grifols and Vall dHebron University Hospital
5. NASDAQ Removes TLCR From Biotechnology Index Pending FTC Decision on Grifols Acquisition
6. Grifols Starts Construction of a New Plasma Fractionation Plant in Barcelona (Parets Del Valles)
7. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
8. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
9. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
10. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
11. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Inc. announced today that its fully owned USA ... York City Office in Yonkers, New York ... (TWO 2 ) homecare therapy. This new East Coast location has ... under the company,s DMEPOS accreditation for Home/Durable Medical Equipment Services. ... Advanced Oxygen Therapy Inc. New ...
(Date:8/8/2017)... 2017   Second-quarter ... (GAAP) loss per share from continuing operations ... increased 16 percent to $110 million ... percent to $161 million ... continuing operations increased 8 percent to $0.93 ...
(Date:8/7/2017)... -- Endo International plc (NASDAQ: ENDP ) today ... known U.S. mesh product liability claims and that it ... U.S. claims at reasonable values. Under the agreements, Endo ... of 2017 and continuing through the fourth quarter of ... the Company intends to increase its mesh product liability ...
Breaking Medicine Technology:
(Date:8/21/2017)... ... August 21, 2017 , ... San Diego physician and surgeon Dr. James Veltmeyer, ... announced his candidacy for the 52nd Congressional District currently held by Representative Scott Peters. ... to this country at age eleven after suffering homelessness and hardship in a distant ...
(Date:8/20/2017)... ... August 20, 2017 , ... A total solar eclipse will occur across ... minutes as the moon moves between the sun and Earth. This rare event will be ... tips can help keep you safe on the road during the total eclipse of the ...
(Date:8/20/2017)... ... August 20, 2017 , ... Are you an adult ... If so, you may be interested in participating in a research study that ... research is to understand more about the relational aspects of adults who have gluten ...
(Date:8/19/2017)... , ... August 18, 2017 , ... ... aimed at creating a transparent, verifiable database to help the cannabis industry move ... technology, Paragon hopes to deliver a faster technology with lower fees. Paragon will ...
(Date:8/19/2017)... Toronto, ON (PRWEB) , ... August 19, 2017 , ... ... of the of NaturallyCurly.com® The Curl Leaders, Editors’ Choice 2017 Award for the second ... must-have accessory for hair stylists and curlies alike was voted Best Moisturizer for Type ...
Breaking Medicine News(10 mins):